Accessibility Menu
 
Rigel Pharmaceuticals logo

Rigel Pharmaceuticals

(NASDAQ) RIGL

Current Price$29.29
Market Cap$545.90M
Since IPO (2000)-95%
5 Year-15%
1 Year+53%
1 Month+7%

Rigel Pharmaceuticals Financials at a Glance

Market Cap

$545.90M

Revenue (TTM)

$294.28M

Net Income (TTM)

$367.02M

EPS (TTM)

$18.91

P/E Ratio

1.56

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$29.29

Volume

80,770.695

Open

$29.54

Previous Close

$29.54

Daily Range

$29.27 - $30.06

52-Week Range

$16.88 - $52.24

RIGL: Motley Fool Moneyball Superscore

76

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rigel Pharmaceuticals

Industry

Biotechnology

Employees

174

CEO

Raul R. Rodriguez, MBA

Headquarters

South San Francisco, CA 94080, US

RIGL Financials

Key Financial Metrics (TTM)

Gross Margin

93%

Operating Margin

43%

Net Income Margin

1%

Return on Equity

186%

Return on Capital

30%

Return on Assets

71%

Earnings Yield

64.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$545.90M

Shares Outstanding

18.48M

Volume

80.77K

Avg. Volume

349.24K

Financials (TTM)

Gross Profit

$274.66M

Operating Income

$125.47M

EBITDA

$127.88M

Operating Cash Flow

$75.66M

Capital Expenditure

$0.00

Free Cash Flow

$75.66M

Cash & ST Invst.

$154.96M

Total Debt

$53.30M

Rigel Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$69.80M

+21.2%

Gross Profit

$63.85M

+23.2%

Gross Margin

91.47%

N/A

Market Cap

$545.90M

N/A

Market Cap/Employee

$3.37M

N/A

Employees

162

N/A

Net Income

$268.06M

+1769.2%

EBITDA

$21.33M

+20.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$101.65M

+485.7%

Accounts Receivable

$51.76M

+24.4%

Inventory

$11.51M

+91.7%

Long Term Debt

$22.88M

-56.3%

Short Term Debt

$30.43M

+302.6%

Return on Assets

71.46%

N/A

Return on Invested Capital

30.28%

N/A

Free Cash Flow

$21.99M

+51.9%

Operating Cash Flow

$21.98M

+51.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FDMT4D Molecular Therapeutics, Inc.
$9.59+1.59%
PRTAProthena Corporation plc
$10.98+1.76%
AKBAAkebia Therapeutics, Inc.
$1.45-3.67%
BCYCBicycle Therapeutics plc
$4.85-1.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
DGXXDigi Power X
$5.42+0.37%
NOKNokia
$13.57+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.15-0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.76+0.01%

Questions About RIGL

What is the current price of Rigel Pharmaceuticals?

Rigel Pharmaceuticals is trading at $29.28 per share.

What is the 52-week range for Rigel Pharmaceuticals?

Over the past 52 weeks, Rigel Pharmaceuticals has traded between $16.88 and $52.24.

How much debt does Rigel Pharmaceuticals have?

As of the most recent reporting period, Rigel Pharmaceuticals reported total debt of $53.30M.

How much cash does Rigel Pharmaceuticals have on hand?

Rigel Pharmaceuticals reported $40.58M in cash and cash equivalents in its most recent financial results.

What is Rigel Pharmaceuticals’s dividend yield?

Rigel Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.